Atrium Therapeutics, Inc. Common Stock (RNA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.31 (-2.62%), Market cap $0.23B, 52-week low–high $12.32 ~ $16.54.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Financial statements, price targets, institutional (13F) holdings and related news for Atrium Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Atrium Therapeutics, Inc. Common Stock trades at $9.31 (-2.62%). Real-time quotes and charts are available on BlackAll Trade.
Atrium Therapeutics, Inc. Common Stock has a market cap of about $0.23B.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The compan